Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of REV-102

Next Previous
Trial Profile

Clinical study of REV-102

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REV 102 (Primary)
  • Indications Hypophosphatasia
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 05 May 2025 According to a Recursion Pharmaceuticals media release,initiation of this phase 1 trial is expected 2H 2026.
  • 08 Apr 2025 According to Rallybio media release, REV102, an ENPP1 inhibitor for the treatment of patients with HPP under development through a joint venture with Recursion Pharmaceuticals, entered investigational new drug application (IND)-enabling studies in the first quarter of 2025 to support the initiation of a Phase 1 study in 2026.
  • 18 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top